Hot Zock OTCBB: BOCX
Seite 1 von 2 Neuester Beitrag: 15.07.04 20:20 | ||||
| Eröffnet am: | 03.04.04 17:51 | von: usZocker | Anzahl Beiträge: | 41 |
| Neuester Beitrag: | 15.07.04 20:20 | von: lancerevo7 | Leser gesamt: | 7.514 |
| Forum: | Hot-Stocks | Leser heute: | 13 | |
| Bewertet mit: |  | |||
| Seite: < | 2 > | ||||
Opening Price : 53 cents
10 Day target: $1.75
3 Month Target: $3.89
Approx. Float: 6 million
A Few Reasons to Own BOCX:
1.. BOCX has patented and proprietary technology that is leading the way in early cancer detection.
2.. BOCX is currently developing and commercializing cancer diagnostic products based upon their breakthrough RECAFTM cancer marker technology.
3.. A vaccine based on BOCX's proprietary RECAFTM technology that would protect against most types of cancer has a $2B market potential in U.S. alone.
4.. Radioisotope imaging of RECAFTM positive cancer cells can be obtained with standard hospital equipment. Projected as a $1B U.S. market share for BOCX.
5.. $ 2 Billion Dollar market targeted for BOCX's single serum test for the diagnosis of numerous types of cancer. To be launched under the name Serum-RECAFTM.
6.. $3 Billion Dollar market share is seen as realistic as BOCX joins the Antibody Therapy arena with very favorable results from preliminary studies based on BOCX's RECAFTM technology.
7.. BOCX targets growing market for minimizing or eliminating side effects of cancer chemotherapy, utilizing its RECAFTM antibodies for drug and radioisotope delivery.
8.. BOCX is seen as a prime-licensing candidate based on the multitude of clinical uses of BOCX's proprietary RECAF TMtechnology.
9.. BOCX has assembled a team of renowned individual scientists and experts under the direction of Dr. Phillip Gold, the most eminent investigator in the cancer marker field.
10.. Investigators at BOCX have demonstrated that leukemia can be diagnosed and monitored utilizing BOCX's RECAFTM staining technology. By cleansing patients' bone marrow of cancer cells, need for bone marrow transplants might be eliminated.
11.. BOCX's Histo-RECAFTM, a special cancer detection kit for tissues, has been cleared for sale by the FDA for U.S. markets, with an early projected market potential of $200 million.
12.. Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.
ABOUT BOCX
BOCX is biotechnology company dedicated to the development of innovative healthcare solutions for the new millennium. The first of these groundbreaking new technologies is in the field of cancer diagnosis, tumor imaging, and treatment. The technology identifies a widespread cancer biomarker known as RECAFTM, which enables the potential for detection of the vast majority of malignant cancers from blood tests, tissue biopsies or other specimen types.
Put simply, RECAFTM is the only biomarker known to be present in most types of cancer cells and BOCX's patented technology is the only means to detect it. What's more, RECAFTM technology distinguishes cancer cells from normal cells and malignant tumors from benign tumors.
Research indicates RECAFTM is present in practically 100% of breast cancers and in approximately 90% of cancers overall. The technology may also be applied to pinpoint the exact location of a cancer in the body using imaging technology. It is anticipated that RECAFTM will replace certain other biomarkers that may only detect one type of cancer or are not sensitive or specific to a particular malignancy. Its widespread nature indicates that RECAFTM technology may be applied to cancers for which there are no other effective markers - particularly breast and lung cancers, which together represent one third of all cancers.
In addition to the USA, BOCX has patents pending for RECAFTM in more than 20 countries and has already received patents in Australia and Russia.
Investment Opportunity
BACKGROUND
In North America, there are over 8 million cancer patients and approximately 1 million new cases are reported each year. Over 1/3 of the population will develop cancer at some point during their life and over one-half million people die from cancer each year. The new incidences of cancer along with the maintenance of persons living with cancer will continue to increase the demand for cancer products. The present world market for cancer therapeutics is approximately US$12 billion per year. The National Cancer Institute estimates overall annual costs for cancer in the U.S. at US$104 billion with US$35 billion in direct medical costs and the remainder in productivity and mortality-related costs. Approximately 1/2 of the direct costs are related to the treatment of breast, lung and prostate cancers.
TECHNOLOGY
A novel widespread cancer marker named RECAFTM. Cancer markers' are molecules that appear on cancer cells but not on normal cells and finding new ones is one of the most important goals in cancer research (only half a dozen have been found in the past 40 years). PSA (prostate cancer) and CEA (colorectal cancer) are well known cancer markers. They can by used to detect (diagnose) and then specifically target cancer cells (therapy) -- offering the potential to provide treatment of cancer by delivering antibodies, drugs and radiation to the targeted cancerous cells.
PRODUCTS
Histo-RECAFTM HAS BEEN CLEARED BY THE FDA FOR SALE IN THE USA.
Its sister product, Cryo RECAFTM - for use for diagnosis on frozen sections while the patient is under anesthesia - is fully developed and awaiting further testing prior to FDA submission. BOCX is actively working on the serum test, which will be launched under the name Serum- RECAFTM.
MARKET POTENTIAL IN THE USA ALONE
Pathology $200M
Blood tests $2B
Imaging $1B
Antibody therapy $3B
RECAF Vaccine $2B
Valuation
How many times have you seen issues explode but you couldn't get your hands on them? We are alerting you to a special company with a unique product that is set to explode on Monday -- this is your chance to get in! BOCX is a high-growth microcap issue and should be purchased only by stock traders and investors that set aside a portion of their portfolio for this type of investment. BOCX is an exciting company with an exciting new technology -- go get it now!
FRIDAY, APRIL 02, 2004 4:56 PM
- BusinessWire
BOCX
0.539 +0.129
Enter Symbol:
Enter Keyword:
RANCHO SANTA MARGARITA, Calif., Apr 2, 2004 (BUSINESS WIRE) -- Dr. Ricardo Moro, President and CEO, BioCurex Inc. (BOCX) released the company's corporate forecast for 2004.
The core of BioCurex's technology is the discovery and subsequent patenting related to a molecule found on cancer cells that is practically absent from normal cells or benign tumor cells. The molecule serves as a cancer "marker" that is found on the surface as well as inside a cancer cell. The company has called it RECAF(TM).
Initially, the company developed and reported on a tissue test (Histo-RECAF) and received FDA recognition for its ability to detect cancer cells. The product development and subsequent approval provided early proof of concept for its technology.
In 2003, the company developed and tested a blood test for RECAF(TM) that is unparalleled in its ability to detect many types of cancer with 90% sensitivity and 95% specificity in the cancers the company has studied to date. No other company can make this claim; BioCurex has superb technology.
The types of malignancies in which the assay has been shown to work cover 60% of all types of cancers. Therefore, it is reasonable to suggest that the Serum-RECAF(TM) test could find use in general screening of many populations, enabling an early diagnosis of any of these cancers. Early detection is the key to providing improved prognosis for all cancer patients. Further, the test should find early use in the monitoring of cancer patients who have received treatment, but who must be regularly evaluated for any recurrence of cancer.
hast du auch ???
Totalverlust nicht ausgeschlossen.
Muss ein jeder selbst einschätzen können, wenn er soetwas ordert. Die Aktie gibt es nur über USA daher weis der Käufer schon in was er investiert.
kannst du mir noch kurz folgende fragen beantworten ?
- von wem stammt das kursziel: 10 days 1,75 und 90 days 3,89 ??? wann ist das erschienen ???
- hast du selbst auch diese biocurex gekauft ?
Die Gefahr das Schulbuben diese Ordern, mir dann einen Strick drehen ist zu gross.
bin sehr interessiert
greez lancer
500% in einer wo. scheint mir ein bisschen sehr pushverdächtig. hab mir das unternehmen mal angeschaut , sind auch noch in der entwicklung, sollte es pos. für die laufen, dann könnten höhere kurse hier schon kommen.
gruss
310367a
die geht ab wie schmitz´s katze, nur leider nicht dabei. mal schauen was die morgen macht. hätt ich nicht gedacht.
rück raus von wo die diesen tip und kursziele hast. das erste ist ja schon übertroffen. RESPEKT ; RESPEKT, kann ich da nur sagen.
gruss
310367a
hast du schon wieder so ein tipp auf lager ???
von wo hast du diesen tipp ?
*hutzieh* lancer
ich gestehe das ich ex-preisfuchs bin.
kann ich in zukunft hier normal posten, ohne das ihr mich immerzu anmacht?
ihr seht doch, dass ich es doch nur gut mit euch meine und lass euch an meinen zocks
gratis
teilhaben. wo bekommt ihr das?
frohe ostern das war ein ostergeschenk für den, der es gecheckt hat und gekaut hat.
good trade
leben und leben lassen. der unwissende redet, der wissende schweigt.
ihr seht doch das ich eine topp quelle zum geldverdienen bin, wenn ihr mich nicht blöd von der seite anmacht.
jetzt aber schluss sonst bekomm ich noch ärger wegen insider wissen *gg*
BioCurex Blood Test Detects 90% of Leading Cancer Killer
MONDAY, APRIL 05, 2004 8:30 AM
- BusinessWire
BOCX
1.80 +1.261
RANCHO SANTA MARGARITA, Calif., Apr 5, 2004 (BUSINESS WIRE) -- BioCurex Inc. (BOCX) announces results for lung cancer detection using its proprietary Serum-RECAF(TM) blood test. The results confirm 90% sensitivity with 95% specificity*.
The findings further substantiate the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers.
The study included 32 lung cancer patients and 103 normal donors with statistical verification.
Dr. Moro commented: "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiation. It is gut wrenching to realize that even thought this is a preventable disease, the number of new cases and deaths keeps increasing each year. It is well established that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives. Moreover, there is no other blood test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous."
These results are consistent with those obtained for other types of cancer and strengthen the concept of using Serum-RECAF(TM) as a valid test for screening the general populations for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology in human and market terms is significant.
Dr. Moro further stated, "It is not well understood by the general public, that we have very few methods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests. This is why RECAF is such a valuable technology. Even if we could only detect one type of cancer, we would have a significant discovery, but the studies demonstrate that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company."
About lung cancer:
Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of death. Lung cancer accounts for 14% of all cancers and 28% of all cancer deaths. At present, more Americans die from lung cancer than from breast, prostate, and colorectal cancers combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximately $97.2 billion each year in health-care costs and lost productivity. It is directly responsible for 87 percent of lung cancer cases and causes most cases of emphysema and chronic bronchitis.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX) , visit our website at www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
* Sensitivity is the number of true cancers picked by the test. Specificity is the percentage of normal samples that are negative with the test. Since 100% specificity is usually unattainable in biological systems, sensitivity is measured at an accepted specificity value of 95%.
nochmal herzlichen glückwunsch preisfuchs, dass war eine punktlandung der ersten klasse , kann ich da nur sagen. meinen respekt hast du und sollte ich ein mal an dir (schriftlich oder mündlich) gezweifelt haben, so ist dieser zweifel hiermit ausgeräumt.
wird nicht leicht sein zu toppen.
gruss
310367a
donini inc. +780% in ca. 4 tagen !
jedenfalls hammmerumsatz in den usa.
gruss
310367a